2021 Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãß°èÇмú´ëȸ : 2021-10-29±³À°ÀÏÀÚ : 2021-10-29
±³À°Àå¼Ò : ¼¿ï ¹Ð·¹´Ï¾öÈúÆ°È£ÅÚ, ÁöÇÏ1Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
2021 Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 60,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 11:00~11:30 ¼ö¿ù¼ºÀÌ È®º¸µÈ ¿¬±¸¸¦ À§ÇÑ Á¦¾ð ¹ÚÇåÁÖ(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 11:30~12:00 3D Cancer Genome: A new method to predict the functional consequences of structural variation Á¤Àΰæ(KAIST)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 12:00~12:30 TME of early lung adenocarcinoma from non-smokers and its usefulness as a therapeutic target ÀåÀ±¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 12:30~13:30 Synergy of IO/IO combination in NSCLC 1L and Mesothelioma 1L ¹Ú¼øÈ¿(°è¸íÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 13:30~14:00 Isolation and characterization of extracellular vesicles ¹ÚÀ缺(Æ÷Ç×°ø´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 14:00~14:30 Next Generation Proteomics of Extracelullar Vesicles in Lung Adenocarcinoma. ¹éÁ¦Çö((Àç)¾¾Á¨ÀÇ·áÀç´Ü)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 14:30~15:00 Exosome-based BALiquid EGFR genotyping in real world practice ±èÈñÁ¤(°Ç±¹ÀÇ´ë)
ÈÞ½Ä 10-29 15:00~15:30 Coffee break ()
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 15:30~16:00 Current status and updates of lung cancer diagnosis in Korea ±è·ç½Ã¾Æ(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 16:00~16:30 Evolution of lung cancer and its clinical implication: A pathologist¡¯s view ÀÌ¿ÁÁØ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 16:30~17:00 Digital pathology: Current status and future direction ÀåÇýÀ±(µö¹ÙÀÌ¿À)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 17:00~17:15 Identication of the role of regulatory T cell as predictive biomarker for ecacy of immune checkpoint blockade in lung cancer ÀÌÁ¤Àº(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10-29 ÁöÇÏ1Ãþ ±×·£µåº¼·ë 17:15~17:30 Afatinib mediates autophagic degradation of ORAI1, STIM1, and SERCA2, which inhibits proliferation of non-small cell lung cancer cells ¾ç¼¼ÈÆ(¿ø±¤ÀÇ´ë)